After a notice appeared yesterday on the FDA website indicating that Elekta had issued a recall on its Unity system, Piper Jaffray analyst Matt O'Brien said he does not want to overstate the impact of this specific recall on ViewRay's (VRAY) ability to win business, but he does think that it highlights the superiority of the MRIdian system compared to Elekta's Unity platform. The analyst, who continues to believe that ViewRay's system is superior not only to Elekta in the MRgRT space but also when compared to "the dominant player," Varian Medical (VAR), keeps an Overweight rating and $15 price target on ViewRay shares.